| 1 |
Khan K, Hunter IA，Manzoor T. Should the rectal defect be sutured following tems/tamis carried out for neoplastic rectal lesions：a meta-analysis[J]. Ann R Coll Surg Engl, 2020, 102(9)：647-653.
|
| 2 |
Hong KD, Kang S, Urn JW, et al. Transanal minimally invasive surgery (TAMIS) for rectal lesions: a systematic review[J]. Hepatogastroenterology, 2015, 62(140)：863-867.
|
| 3 |
Baker EJ, Waters PS, Peacock O, et al. Robotic transanal minimally invasive surgery- technical, oncological and patient outcomes from a single institution[J]. Colorectal Dis, 2020, 22(10)：1422-1428.
|
| 4 |
邹贵军，袁新普，马冰，等. 达芬奇机器人经肛门微创手术：治疗直肠良性肿瘤的一种新技术[J/CD]．中华腔镜外科杂志(电子版)，2022，25(3)：187-190.
|
| 5 |
Benson AB, Venook A, Al-Hawary MM, et al. Nccn guidelines insights: colon cancer, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(4)：359-369.
|
| 6 |
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(4): 263.
|
| 7 |
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9)：835-844.
|
| 8 |
Lenfant C，Williams TF. " Prudence" and " evidence" in disease prevention[J]. J Clin Epidemiol, 1992, 45(8)：925-927.
|
| 9 |
Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study[J]. Ann Oncol, 2016, 27(5)：834-842.
|
| 10 |
Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer[J]. J Clin Oncol, 2006, 24(4)：668-674.
|
| 11 |
Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results[J]. Ann Surg, 2004, 240(4)：711-717.
|
| 12 |
Martin ST, Heneghan HM，Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer[J]. Br J Surg, 2012, 99(7)：918-928.
|
| 13 |
Rullier E, Vendrely V, Asselineau J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the greccar 2 randomised trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(5)：465-474.
|
| 14 |
Hiotis SP, Weber SM, Cohen AM, et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients[J]. J Am Coll Surg, 2002, 194(2)：131-135.
|
| 15 |
Valentini V, Gambacorta MA, Cellini F, et al. The interact trial: long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for ct2 (distal)-ct3 rectal cancer[J]. Radiother Oncol, 2019, 134：110-118.
|
| 16 |
Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase Ⅲ trial accord 12/0405-prodige 2[J]. J Clin Oncol, 2010, 28(10)：1638-1644.
|
| 17 |
Ngu JC, Kuo LJ, Kung CH, et al. Robotic transanal minimally invasive surgery for rectal cancer after clinical complete response to neoadjuvant chemoradiation[J]. Int J Med Robot, 2018, 14(5)：1948.
|
| 18 |
Tomassi MJ, Taller J, Yuhan R, et al. Robotic transanal minimally invasive surgery for the excision of rectal neoplasia: clinical experience with 58 consecutive patients[J]. Dis Colon Rectum, 2019, 62(3)：279-285.
|